Yahoo Finance·2026-01-27 18:35Group 1: Viking Therapeutics - Viking Therapeutics is focused on developing weight-loss medicines, with its leading candidate VK2735 currently in phase 3 studies in a subcutaneous formulation [3] - The mid-stage results for VK2735 are reportedly stronger than those of larger competitors, and the company is also working on an oral version of the drug [3] - Viking Therapeutics is exploring different dosage schedules and formulations to help patients maintain weight loss [4] - The company plans to initiate clinical trials for a new weight management candidate this year, with significant clinical progress expected in 2026 [5] - The stock could see an increase this year if the company achieves clinical and regulatory successes through 2028, potentially leading to superior long-term returns [6] Group 2: BioNTech - BioNTech has faced inconsistent revenue from its coronavirus vaccine, which it shares with Pfizer, but ongoing clinical progress may improve its financial outlook [7] - Important data readouts are anticipated through 2026, including an interim analysis for BNT113, an investigational cancer medicine for head and neck cancer [7][8] - BNT113 has received Fast Track Designation from the U.S. Food and Drug Administration, which may expedite its development and approval process [8]